Patent ID: 8246960

Claim:
A method of treating a human lymphoma or leukemia comprising: a) obtaining a complex comprising, (i) an adaptor module selected from the group consisting of HSP70, α 2 macroglobulin, HSA (human serum albumin), hP1 (human protamine 1), a heat shock protein, a human protamine and an Fc fragment of a human antibody; (ii) a first peptide and a second peptide, each peptide attached to the adaptor module and each peptide comprising an AD moiety or a DDD moiety, wherein the peptide sequence of the AD moiety is selected from the group consisting of AD2 (SEQ ID NO:2) and AD3 (SEQ ID NO:5) and the peptide sequence of the DDD moiety is selected from the group consisting of DDD2 (SEQ ID NO:1), DDD3 (SEQ ID NO:3) and DDD3C (SEQ ID NO:4); and (iii) a first effector moiety and a second effector moiety, each effector moiety selected from the group consisting of an antibody, an antigen-binding antibody fragment thereof having a binding affinity for a tumor-associated antigen and cytokine; and b) administering the complex to a human subject with lymphoma or leukemia.